is a boutique law firm handling complex and class action litigation, including shareholder derivative litigation, securities class actions, data breach and consumer class actions.

Current Securities Class Action Cases

Federman & Sherwood regularly posts press releases about new class action securities cases, which includes the class period and deadlines for appointment of lead plaintiffs.  Please review any of the case listings  below, and if you bought a security during the class period, we invite you to return an investor certification to our office. Our link to an investor certification for any of the cases can be found below each respective press release on that company.  Once completed, please return to our office by email to rkh@federmanlaw.com or fax to (405) 239-2112. 

Current Cases

Puma Biotechnology, Inc. [NASDAQ: PBYI]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Puma Biotechnology, Inc.

Oklahoma City, OK (May 15, 2017) – On May 8, 2017, a securities class action lawsuit was filed in the United States District Court for the Central District of California against Puma Biotechnology, Inc. (NASDAQ: PBYI). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is February 29, 2016 through May 4, 2017. More specifically, this litigation was filed because Defendants made false and/or misleading statements and/or failed to disclose during the Class Period that: (i) the Company did not anticipate that the U.S. Food and Drug Administration’s (“FDA”) would ultimately approve neratinib for the treatment of breast cancer; (ii) as such, Puma had overstated the drug’s approval prospects and/or commercial viability; and (iii) as a result, Puma’s public statements were materially false and misleading at all relevant times.

On May 4, 2017, post-market, Puma disclosed the resignation of Dr. Robert Charnas, the Company’s Senior Vice President, Regulatory Affairs, citing “health reasons.” Dr. Charnas’ resignation will be effective as of May 15, 2017, nine days before the FDA scheduled review of Puma’s breast cancer drug neratinib on May 24. On this news, Puma’s share price fell $5.85 to close at $30.70 on May 5, 2017.

Plaintiff seeks to recover damages on behalf of all Puma Biotechnology, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Friday, July 7, 2017 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

To join this class action, click here to obtain an investor certification. Once complete, please email this form to rkh@federmanlaw.com, fax to us at (405) 239-2112 or send by regular mail to Federman & Sherwood, 10205 North Pennsylvania Avenue, Oklahoma City, OK 73120, ATTN: Robin.

Copyright © 2017 Federman & Sherwood. All Rights Reserved.